EverSource Wealth Advisors LLC Grows Stock Position in argenx SE (NASDAQ:ARGX)

EverSource Wealth Advisors LLC increased its position in shares of argenx SE (NASDAQ:ARGX) by 23.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 121 shares of the company’s stock after buying an additional 23 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in argenx were worth $74,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ARGX. Victory Capital Management Inc. raised its position in shares of argenx by 69.8% during the 3rd quarter. Victory Capital Management Inc. now owns 1,562 shares of the company’s stock valued at $847,000 after buying an additional 642 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in shares of argenx during the 3rd quarter valued at approximately $453,000. OneDigital Investment Advisors LLC raised its position in shares of argenx by 13.2% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 1,194 shares of the company’s stock valued at $647,000 after buying an additional 139 shares during the period. Natixis Advisors LLC raised its position in shares of argenx by 13.0% during the 3rd quarter. Natixis Advisors LLC now owns 12,014 shares of the company’s stock valued at $6,513,000 after buying an additional 1,379 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in shares of argenx by 1.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 37,352 shares of the company’s stock valued at $20,248,000 after buying an additional 564 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $611.18 on Wednesday. argenx SE has a one year low of $349.86 and a one year high of $678.21. The company has a 50-day simple moving average of $636.83 and a 200-day simple moving average of $598.22. The stock has a market capitalization of $37.14 billion, a price-to-earnings ratio of -694.52 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. As a group, research analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the topic of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $655.00 price target on shares of argenx in a research report on Tuesday, December 3rd. Evercore ISI lifted their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Piper Sandler lifted their target price on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. William Blair reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.